Orquest plans autumn IDE submission for Healos collagen-based bone grafting material.
This article was originally published in The Gray Sheet
Executive Summary
ORQUEST HEALOS BONE GRAFTING MATERIAL ENTERS CLINICALS in Europe, the company says. Mountain View, California-based Orquest announced June 18 that it has commenced patient enrollment in a feasibility study evaluating use of the resorbable hydroxyapatite-coated collagen fiber material in spinal fusion procedures for patients with degenerative disc disease (DDD).